PubMed Health⌕ Search

Biomedical subjects

Kayode Ogungbenro

Publications and source records attributed to Kayode Ogungbenro.

4 recordsLinked to original sources

Optimal design for multivariate response pharmacokinetic models.

We address the problem of designing pharmacokinetic experiments in multivariate response situations. Criteria, based on the Fisher information matrix, whose inverse according to the Rao-Cramer inequality is the lower bound of the variance-covariance matrix of any unbiased estimator of the parameters, have previously been developed for univariate response for an individual and a population. We extend these criteria to design individual and population studies where more than one response is measured, for example, when both parent drug and metabolites are measured in plasma, multi-compartment models, where measurements are taken at more than one site, or when drug concentration and pharmacodynamic data are collected simultaneously. We assume that measurements made at distinct times are independent, but measurements made of each concentration are correlated with a response variance-covariance matrix. We investigated a number of optimisation algorithms, namely simplex, exchange, adaptive random search, simulated annealing and a hybrid, to maximise the determinant of the Fisher information matrix as required by the D-optimality criterion. The multiresponse optimal design methodology developed was applied in two case studies, where the aim was to suggest optimal sampling times. The first was a restrospective iv infusion experiment aimed to characterise the disposition kinetics of tolcapone and its two metabolites in healthy volunteers. The second was a prospective iv bolus experiment designed to estimate the tissue disposition kinetics of eight beta-blockers in rat.

Adrenergic beta-Antagonists↗

Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.

We present a method for calculating the sample size of a pharmacokinetic study analyzed using a mixed effects model within a hypothesis testing framework. A sample size calculation method for repeated measurement data analyzed using generalized estimating equations has been modified for nonlinear models. The Wald test is used for hypothesis testing of pharmacokinetic parameters. A marginal model for the population pharmacokinetic is obtained by linearizing the structural model around the subject specific random effects. The proposed method is general in that it allows unequal allocation of subjects to the groups and accounts for situations where different blood sampling schedules are required in different groups of patients. The proposed method has been assessed using Monte Carlo simulations under a range of scenarios. NONMEM was used for simulations and data analysis and the results showed good agreement.

Computer Simulation↗

The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments.

We propose a new algorithm for optimising sampling times for population pharmacokinetic experiments using D-optimality. The algorithm was used in conjunction with the population Fisher information matrix as implemented in MATLAB (PFIM 1.1 and 1.2) to evaluate population pharmacokinetic designs. The new algorithm based on the classical Fedorov exchange algorithm optimises the determinant of the population Fisher information matrix. The performance of the new algorithm has been compared with other existing algorithms including simplex, simulated annealing and adaptive random search. The new algorithm performed better especially when dealing with complex designs at the expense of longer computing times.

Algorithms↗

Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.

The objective of this paper is to determine optimal blood sampling time windows for the estimation of pharmacokinetic (PK) parameters by a population approach within the clinical constraints. A population PK model was developed to describe a reference phase II PK dataset. Using this model and the parameter estimates, D-optimal sampling times were determined by optimising the determinant of the population Fisher information matrix (PFIM) using PFIM_ _M 1.2 and the modified Fedorov exchange algorithm. Optimal sampling time windows were then determined by allowing the D-optimal windows design to result in a specified level of efficiency when compared to the fixed-times D-optimal design. The best results were obtained when K(a) and IIV on K(a) were fixed. Windows were determined using this approach assuming 90% level of efficiency and uniform sample distribution. Four optimal sampling time windows were determined as follow: at trough between 22 h and new drug administration; between 2 and 4 h after dose for all patients; and for 1/3 of the patients only 2 sampling time windows between 4 and 10 h after dose, equal to [4 h-5 h 05] and [9 h 10-10 h]. This work permitted the determination of an optimal design, with suitable sampling time windows which was then evaluated by simulations. The sampling time windows will be used to define the sampling schedule in a prospective phase II study.

Administration, Oral↗